Selecting an optimal pharmacotherapy for allergic rhinitis from the standpoint of guidelines and observation in real-life clinical practice

Introduction. Allergic rhinitis (AR) is a common condition that has considerable impact on patients’ quality of life. Moreover, it is the risk factor for asthma development. Therefore, achieving control of AR remains crucial.
Aim. To analyze comparative efficacy of fixed-dose combination of olopatadine hydrochloride – mometasone furoate versus combination of intranasal corticosteroids with second generation oral antihistamines.
Materials and methods. Seventy-five patients (ages 19–59) mainly with moderate severity of AR enrolled the study. Group 1 (29 patients) was given a fixed-dose combination of olopatadine hydrochloride – mometasone furoate (Ryaltris) in 2 sprays (25/600 mcg) in each nostril twice daily, whereas group 2 (46 patients) – intranasal corticosteroids with second generation oral antihistamines for 14 days. The efficacy was evaluated using validated questionnaires and scales (TNSS, TOSS, VAS, SNOT-22) before, during and after the treatment is complete.
Results and discussion. We revealed AR and allergic conjunctivitis symptoms improvement as well as quality of life parameters. Nevertheless, disease control was achieved earlier (on day 2 of treatment) in group 1, while in group 2 – only on day 4.
Conclusions. Our study showed comparable efficacy of fixed-dose combination of olopatadine hydrochloride – mometasone furoate (Ryaltris) and combination of intranasal corticosteroids with second generation oral antihistamines. However, fixed-dose combination topical therapy is associated with lower risk of adverse reactions and leads to early control of AR and allergic conjunctivitis symptoms. Besides, fixed combination use adjusts adherence to treatment.

1. Astafieva N.G., Baranov A.A., Vishneva E.A., Daikhes N.A., Zhestkov A.V., Ilyina N.I. et al. Allergic rhinitis: clinical guidelines. Moscow; 2020. (In Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/261_1.

2. Astafieva N.G., Baranov A.A., Vishneva E.A., Daikhes N.A., Zhestkov A.V., Ilina N.I. et al. Allergic rhinitis. Russian Journal of Allergy. 2022;19(1):100–141. (In Russ.) https://doi.org/10.36691/RJA1524.

3. Khaitov M.R., Namazova-Baranova L.S., Ilyina N.I., Kurbacheva O.M., Bachert C., Hellings P.W. et al. 2019 ARIA: care pathways for allergic rhinitis in Russia. Russian Journal of Allergy. 2020;17(1):7–22. (In Russ.) https://doi.org/10.36691/RAJ.2020.17.1.001.

4. Ilina N.I. Allergy in Russia today: problems and solutions. Russian Journal of Allergy. 2022;19(3):285–288. (In Russ.) https://doi.org/10.36691/RJA1566.

5. Skorokhodkina O.V., Arkhipova S.A., Klykova T.V., Zaynetdinova G.M., Kruglova E.B., Volkova D.A. Dynamics of the cytokine profile in achieving the therapeutic effect of allergen-specific immunotherapy in children with allergic rhinitis and bronchial asthma. Russian Bulletin of Perinatology and Pediatrics. 2021;66(5):176–182. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-5-176-182.

6. Hahn-Pedersen J., Boxall N., Maier W., Linneberg A., Serup-Hansen N. Systematic Literature Review Assessing Data on the Burden of Allergic Rhinitis from a Cost and Quality of Life Perspective. Value Health. 2014;17(7):A602. https://doi.org/10.1016/j.jval.2014.08.2087.

7. Nenasheva N.M., Terekhova E.P., Bodnya O.S., Sebekina O.V. Visual analogue scale – a tool for assessing the control of allergic rhinitis. Russian Journal of Allergy. 2018;15(6):79–88. (In Russ.) https://doi.org/10.36691/RJA114.

8. Zhang Y., Lan F., Zhang L. Advances and highlights in allergic rhinitis. Allergy. 2021;76(11):3383–3389. https://doi.org/10.1111/all.15044.

9. Meng Y., Wang C., Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75(12):3069–3076. https://doi.org/10.1111/all.14586.

10. Bousquet J., Schünemann H.J., Togias A., Bachert C., Erhola M., Hellings P.W. et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. https://doi.org/10.1016/j.jaci.2019.06.049.

11. Passali D., Spinosi M.C., Crisanti A., Bellussi L.M. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. https://doi.org/10.1186/s40248-016-0054-3.

12. Zitt M., Kosoglou T., Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30(4):317–326. https://doi.org/10.2165/00002018-200730040-00004.

13. Hampel F.C., Pedinoff A.J., Jacobs R.L., Caracta C.F., Tantry S.K. Olopatadinemometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40(4):261–272. https://doi.org/10.2500/aap.2019.40.4223.

14. Van Bulck P., Cools L., Soumya M.S., Nyembue D.T., Kabobo P., Zhang L. et al. A multicenter real-life study on the multiple reasons for uncontrolled allergic rhinitis. Int Forum Allergy Rhinol. 2021;11(10):1452–1460. https://doi.org/10.1002/alr.22808.

15. Shilenkova V.V., Nenasheva N.M. Allergic rhinitis: what is the patient’s choice of drug based on? Russian study’s results. Vestnik Oto-RinoLaringologii. 2021;86(2):54–61. (In Russ.) https://doi.org/10.17116/otorino20218602154.

16. Ozdemir P.G., Karadag A.S., Selvi Y., Boysan M., Bilgili S.G., Aydin A., Onder S. Assessment of the effects of antihistamine drugs on mood, sleep

17. quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract. 2014;18(3):161–168. https://doi.org/10.3109/13651501.2014.907919.

18. Li L., Liu R., Peng C., Chen X., Li J. Pharmacogenomics for the efficacy and side effects of antihistamines. Exp Dermatol. 2022;31(7):993–1004. https://doi.org/10.1111/exd.14602.

19. Chen R., Zheng D., Zhang Y., Sima G. Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2022;279(4):1691–1699. https://doi.org/10.1007/s00405-021-07085-w.

20. Phinyo P., Wongsa C., Sompornrattanaphan M., Thongngarm T. As-needed versus regular intranasal corticosteroid for allergic rhinitis: A systematic review and meta-analysis. Asian Pac J Allergy Immunol. 2022;40(3):195–204. https://doi.org/10.12932/AP-091121-1269.

21. Berger W.E., Meltzer E.O. Intranasal spray medications for maintenance therapy of allergic rhinitis. Am J Rhinol Allergy. 2015;29(4):273–282. https://doi.org/10.2500/ajra.2015.29.4215.

22. Wise S.K., Lin S.Y., Toskala E., Orlandi R.R., Akdis C.A., Alt J.A. et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. https://doi.org/10.1002/alr.22073.

23. Bodnya O.S., Nenasheva N.M., Andrenova G.V., Sinyavkin D.O., Bodnya Ya.V., Kubanova E.T. Comparative efficacy of different antihistamines 2-го generation in adult patients with seasonal allergic rhinitis. Consilium Medicum. 2017;19(3):101–108. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/94881.

24. Husain Q., Hoehle L., Phillips K., Caradonna D.S., Gray S.T., Sedaghat A.R. The 22-Item Sinonasal Outcome Test as a Tool for the Assessment of Quality of Life and Symptom Control in Allergic Rhinitis. Am J Rhinol Allergy. 2020;34(2):209–216. https://doi.org/10.1177/1945892419884789.

25. Glantz S.A. Primer of Biostatistics. 4th ed. New York: McGraw Hill; 1997. 455 p.

26. Lim L., Lipari M., Kale-Pradhan P. Intranasal Olopatadine: Mometasone in the Treatment of Seasonal Allergic Rhinitis. Ann Pharmacother. 2022:10600280221124230. https://doi.org/10.1177/10600280221124230.

27. Segall N., Prenner B., Lumry W., Caracta C.F., Tantry S.K. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2019;40(5):301–310. https://doi.org/10.2500/aap.2019.40.4233.

28. Baiardini I., Novakova S., Mihaicuta S., Oguzulgen I.K., Canonica G.W. Adherence to treatment in allergic respiratory diseases. Expert Rev Respir Med. 2019;13(1):53–62. https://doi.org/10.1080/17476348.2019.1554438.

29. Köberlein J., Kothe A.C., Sieber J., Mösges R. Determining factors of patient compliance to treatment in allergic rhinitis. Asian Pac J Allergy Immunol. 2013;31(2):148–156. https://doi.org/10.12932/AP0264.31.2.2013.

30. Ellis A.K., Zhu Y., Steacy L.M., Walker T., Day J.H. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013;9(1):16. https://doi.org/10.1186/1710-1492-9-16.

31. Corren J., Storms W., Bernstein J., Berger W., Nayak A., Sacks H. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther. 2005;27(5):543–553. https://doi.org/10.1016/j.clinthera.2005.04.012.

32. Baroody F.M., Naclerio R.M. Nasal-ocular reflexes and their role in the management of allergic rhinoconjunctivitis with intranasal steroids. World Allergy Organ J. 2011;4(Suppl. 1):S1–5. https://doi.org/10.1097/WOX.0b013e3181f32dcd.

33. Bielory L., Chun Y., Bielory B.P., Canonica G.W. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011;66(5):686–693. https://doi.org/10.1111/j.1398-9995.2010.02543.x.